Is CVS/Caremark Intentionally Harming Local Pharmacies?

Florida’s investigation may finally force the PBM question into the open

Independent pharmacies have been saying the same thing for years: the rules of the pharmacy market are not neutral.

A local pharmacy can serve its community, know its patients by name, answer the phone, deliver medications, help seniors navigate confusion, and still lose money on prescriptions because of reimbursement terms it did not negotiate in any meaningful way. It can be audited, clawed back, excluded from preferred networks, underpaid below acquisition cost, or watched as patients are nudged toward a pharmacy owned by the same corporate system that manages the drug benefit.

For years, those complaints were easy for large pharmacy benefit managers to dismiss as anecdotes.

But Florida’s June 2026 subpoena to CVS Health and Caremark changes the posture of the conversation. This is not just another press release about PBMs. It is a formal Civil Investigative Demand (a legal tool that functions much like a subpoena, compelling documents and sworn testimony) from the Florida Attorney General, seeking evidence about whether CVS/Caremark is using its vertically integrated position to harm independent pharmacies and Florida patients.

To be clear: an investigation is not a finding of liability. The allegations still need to be tested. CVS has publicly said it will work with the Florida Attorney General and has argued that PBMs are not the driver of high drug prices.

But the question Florida is asking is the question independent pharmacies have been asking for years:

Is CVS/Caremark using control over drug benefits, pharmacy networks, reimbursement, audits, contracts, rebates, and patient steering to advantage CVS-affiliated pharmacies at the expense of local independent pharmacies?

That question can be answered with evidence. And that is why this investigation is significant.

The core conflict: CVS is not just a pharmacy chain

The Florida Attorney General’s June 23, 2026 release describes the issue as one of vertical integration.

CVS is not only a pharmacy chain. CVS Health owns Caremark, one of the largest pharmacy benefit managers in the country. Caremark helps control which drugs are covered, how much pharmacies are paid, and where patients are encouraged or required to fill prescriptions. CVS also owns more than 9,000 pharmacies nationwide, including roughly 800 in Florida.

That structure creates an obvious concern for local pharmacies.

If the same corporate family can:

• manage the prescription-drug benefit;
• decide or influence network terms;
• affect reimbursement rates;
• design preferred pharmacy arrangements;
• process claims;
• audit pharmacies;
• collect rebate and pricing information;
• and own a competing retail pharmacy chain;

then independent pharmacies are not just competing against another store across town. They may be competing against a vertically integrated system that has visibility into, and influence over, the rules of the market itself.

That does not automatically prove illegal conduct. But it does explain why the Florida investigation carries real weight.

What Florida is investigating

According to the Florida Attorney General, the investigation examines whether CVS/Caremark has engaged in practices that harm local pharmacies and patients.

The conduct under investigation includes whether CVS/Caremark:

• steers patients to CVS locations;
• reimburses CVS-affiliated stores more generously than independent pharmacies for identical prescriptions;
• imposes burdensome audits that claw back payments from local pharmacies;
• enforces restrictive contracts that threaten small businesses.

Florida alleges these practices can contribute to pharmacy closures and pharmacy deserts, reducing choice and increasing costs for families and seniors.

That list is important because it is specific. This is not a vague complaint that “PBMs are bad.” It is an inquiry into concrete business practices that can be documented.

If an independent pharmacy is paid less than a CVS-affiliated pharmacy for the same drug under the same benefit structure, that is measurable. If patient benefit design makes CVS cheaper or easier to use than a local pharmacy, that is measurable. If audits and clawbacks disproportionately hit independent pharmacies, that is measurable. If contract terms make participation technically available but economically impossible, that is measurable.

That is why this Civil Investigative Demand is so consequential: it is about evidence.

Why the Civil Investigative Demand is a turning point

Florida’s Civil Investigative Demand reportedly seeks thousands of documents and sworn testimony.

The requested categories include:

• reimbursement rates;
• pharmacy contracts;
• patient steering;
• audits;
• rebates;
• differential treatment of CVS-owned versus independent stores;
• expansion plans.

The compliance deadline is July 28, 2026.

That deadline creates a meaningful checkpoint. The next stage of this story is not another round of PBM talking points. It is whether Florida obtains evidence that supports a lawsuit, settlement, consent order, public report, coordinated enforcement action, or some other outcome.

For independent pharmacies, this is significant because the industry has long had the lived experience; what's often been missing is regulator-grade evidence.

Patient steering is not a small issue

Patient steering is one of the most important issues in the PBM debate because it affects both pharmacies and patients.

A local pharmacy may have a long-standing relationship with a patient. The pharmacist may know the patient’s medication history, adherence barriers, caregivers, delivery needs, language preferences, and clinical risks.

But if the benefit design, call-center script, mail-order prompt, app interface, or cost-sharing structure nudges the patient away from that pharmacy and toward a PBM-affiliated pharmacy, the patient may experience that shift as a neutral plan rule rather than a corporate steering mechanism.

That is the danger.

Steering does not always look like a hard prohibition. It can look like:

• lower copays at an affiliated pharmacy;
• mail-order defaults;
• warnings that a local pharmacy is “out of network” or “non-preferred”;
• refill reminders that route patients to affiliated channels;
• plan communications that make independent pharmacy use seem more difficult;
• specialty-drug requirements that bypass the local pharmacist;
• network designs that technically include local pharmacies but make them economically uncompetitive.

For an independent pharmacy, even small steering pressures can matter. Losing a portion of recurring prescriptions can undermine staffing, inventory, delivery, and clinical-service capacity.

For a patient, the loss is not only convenience. It can mean losing a trusted healthcare access point.

Reimbursement discrimination is the heart of the independent pharmacy complaint

For local pharmacies, the question is often brutally simple:

Am I being paid enough to keep filling this prescription without losing money?

Independent pharmacists regularly report reimbursement that does not cover acquisition cost, let alone dispensing labor, rent, insurance, delivery, compliance work, inventory risk, and patient counseling.

The Florida investigation appears to focus in part on whether CVS-affiliated pharmacies receive more favorable reimbursement than independent pharmacies for identical prescriptions.

That question is central because it goes directly to competitive fairness.

If a PBM pays its affiliated pharmacy one rate and an independent pharmacy a worse rate for the same prescription, the independent pharmacy is not simply being outcompeted. It may be operating inside a reimbursement environment shaped by its competitor’s corporate affiliate.

The evidence would likely need to compare:

• the same drug or NDC (National Drug Code, the unique identifier for a specific drug product);
• the same plan or benefit structure;
• the same time period;
• the same pharmacy network category;
• acquisition cost benchmarks such as NADAC where available;
• dispensing fees;
• post-adjudication adjustments;
• DIR or similar fees;
• affiliate versus independent pharmacy payment.

This is why independent pharmacies need data. The strongest future complaint will not only say “the PBM underpaid us.” It will show the pattern drug by drug, plan by plan, claim by claim.

Audits and clawbacks can become a competitive weapon

Pharmacy audits have a legitimate purpose. Plans and PBMs need tools to detect fraud, waste, abuse, billing errors, inventory issues, and documentation problems.

But independent pharmacies have long argued that audits can become punitive when they are excessive, technical, asymmetric, or used to claw back money for minor documentation issues long after the prescription was filled and the patient was served.

Florida’s investigation includes burdensome audits and clawbacks among the practices under review.

This distinction is important because audits affect independent pharmacies differently than national chains. A large corporate pharmacy can absorb legal, compliance, and administrative burden in a way a small-town pharmacy often cannot. A major clawback can threaten payroll, inventory purchasing, or survival.

The question is not whether audits should exist. They should.

The question is whether audit practices are fair, proportional, consistently applied, and free from conflicts of interest.

If independent pharmacies are audited more aggressively than affiliated pharmacies, or if audit rules are applied in a way that disproportionately extracts money from local competitors, then audit policy becomes more than compliance. It becomes market power.

Restrictive contracts can exclude pharmacies without saying “you are excluded”

One of the most important concepts in the PBM debate is economic exclusion.

A pharmacy does not have to be formally kicked out of a network to be pushed out of the market. It can be offered contract terms that are technically available but economically impossible.

A contract can be “open” in theory while still being destructive in practice if it includes:

• reimbursement below acquisition cost;
• unpredictable post-adjudication fees;
• audit provisions that create constant clawback risk;
• operational requirements that are expensive for small pharmacies;
• preferred-network terms that shift patients elsewhere;
• quality measures that are poorly fitted to independent pharmacy operations;
• narrow appeal rights;
• take-it-or-leave-it terms.

This is why the federal “reasonable and relevant” Part D contract fight is worth watching closely.

The issue is not only whether any willing pharmacy can sign a contract. The issue is whether the terms are reasonable enough for a real pharmacy to participate without being financially strangled.

The federal Part D fight is moving in the same direction

Florida’s Civil Investigative Demand should be read alongside federal activity around Medicare Part D pharmacy contracting.

NCPA reported that it led the Pharmacy Coalition in meeting with CMS leadership to ask the agency to regulate standards for “reasonable and relevant” pharmacy contract terms under Medicare Part D’s any-willing-pharmacy provisions.

The coalition includes NCPA, APhA, NACDS, ASCP, NASP, and FMI.

The argument is that HHS has authority to establish standards for what counts as reasonable and relevant contract terms, and that CMS has already regulated many Part D contracting-related issues, including network adequacy, preferred cost sharing, credentialing, direct and indirect remuneration, and retail access.

That is the federal counterpart to the Florida investigation.

Florida is seeking evidence about one vertically integrated company’s practices. The federal process is about whether Part D pharmacy contracts should be governed by clearer standards so pharmacies are not offered participation on terms that are unreasonable in practice.

Both point in the same direction: PBM scrutiny is becoming more concrete, more evidentiary, and more focused on enforceable standards.

What reforms are coming into view

According to NCPA’s summary of 2026 Medicare Part D pharmacy reimbursement and PBM reform provisions, the reforms are intended to strengthen community pharmacy participation in Part D and establish fair contracting standards, PBM accountability, and enhanced transparency.

For reasonable-and-relevant terms, the summary says the requirement applies for Part D plan year 2029 and requires PDP sponsors (standalone Medicare Part D prescription drug plans) and MA-PDs (Medicare Advantage plans that include prescription drug coverage) to offer reasonable-and-relevant terms and allow any willing pharmacy to participate if it meets them.

HHS is expected to consider issues such as:

• reimbursement adequacy;
• operational costs;
• audits;
• quality measures;
• contracting practices.

The summary also describes a standardized CMS violation-reporting template, possible civil monetary penalties or sanctions, and anti-retaliation protections.

That last point is worth underlining. Independent pharmacies are often afraid to challenge the entities that control access to patients and reimbursement. Anti-retaliation protections are essential if pharmacies are going to report abusive practices honestly.

Transparency is coming, but local pharmacies need to prepare now

The reform timeline suggests that PBM transparency and payment reform will take on growing weight over the next few years.

Key watch items include:

• July 28, 2026: CVS/Caremark’s Florida CID response deadline;
• April 1, 2027: CMS Request for Information (RFI) deadline for reasonable-and-relevant standards;
• January 1, 2028: PBM transparency and payment reform effective date;
• April 3, 2028: final reasonable-and-relevant standards deadline;
• January 1, 2029: Part D network contract requirements and pharmacy complaint process.

The annual PBM reporting requirement is especially important because it may include data on:

• prescription volume by pharmacy type;
• drug acquisition costs and NADAC (National Average Drug Acquisition Cost) comparisons;
• DIR (direct and indirect remuneration) fees;
• reimbursement and dispensing-fee data;
• affiliate pharmacy payments;
• benefit-design features steering patients to PBM-owned pharmacies.

That is exactly the type of information local pharmacies have needed for years.

If regulators can compare affiliate and independent reimbursement, audit patterns, network design, and patient steering, the PBM debate becomes less about rhetoric and more about market evidence.

What independent pharmacies should document now

Local pharmacies should not wait for regulators to build the entire evidence record.

Independent pharmacies and pharmacy networks should preserve data that shows how PBM practices affect them in the real world.

That includes:

• NDC (National Drug Code);
• plan/PBM;
• date of service;
• acquisition cost;
• NADAC comparison;
• dispensing fee;
• effective reimbursement rate;
• post-adjudication adjustment;
• DIR (direct and indirect remuneration) or similar fees;
• audit or clawback outcome;
• contract provision;
• patient steering artifact;
• pharmacy type;
• affiliate versus non-affiliate comparator where available;
• rejected claim reason;
• preferred-network status;
• patient cost-sharing differential.

This documentation is critical because independent pharmacy economics are becoming an evidence problem.

The most persuasive future complaint will not say only:

We are being treated unfairly.

It will show:

• which claims were underpaid;
• how reimbursement compared with acquisition cost;
• whether affiliated pharmacies received better treatment;
• how audits and clawbacks were applied;
• how contract terms made participation uneconomic;
• how patients were steered away;
• how the pattern affected access in a community.

Why this is significant for patients

This is not only a pharmacy-business issue.

When independent pharmacies close, patients lose access.

That access loss is especially serious for:

• rural communities;
• seniors;
• patients with transportation barriers;
• patients who need delivery;
• patients managing multiple chronic medications;
• caregivers who rely on a pharmacist who knows the patient;
• medically complex patients who need human help, not just a mail-order box.

A local independent pharmacy is often one of the most accessible healthcare sites in a community. It may be the place where a patient asks about side effects, affordability, adherence, duplicate therapy, vaccines, home delivery, or confusing discharge medications.

If PBM practices make local pharmacies financially unsustainable, the harm is not abstract. It shows up as longer drives, fewer choices, delayed fills, less counseling, and weaker community healthcare infrastructure.

CVS’s likely defense deserves to be heard, but it does not end the inquiry

CVS has argued that PBMs are not the driver of expensive medications and that drugmakers set prescription-drug prices.

That point may be partly true in the narrow sense that manufacturers set list prices. But it does not answer the independent pharmacy question.

The Florida investigation is not only about list prices. It is about whether CVS/Caremark uses its position to steer patients, set reimbursement, structure contracts, impose audits, manage rebates, and treat affiliated pharmacies differently than independent pharmacies.

Those are separate questions.

Even if drug manufacturers contribute heavily to high drug prices, that does not resolve whether PBM-owned pharmacy integration creates unfair competitive pressure on local pharmacies.

Both things can be true at once:

• manufacturers can play a major role in high drug prices;
• PBM practices can still harm independent pharmacies and patient access.

The question regulators need to answer

The title question is intentionally direct:

Is CVS/Caremark intentionally harming local pharmacies?

The legally careful answer today is: Florida is investigating allegations that point in that direction, but the evidence still needs to be tested.

The practical answer from the independent pharmacy perspective is: the pattern local pharmacies describe is too consistent to ignore.

If a vertically integrated PBM can pay local pharmacies less, audit them harder, offer them take-it-or-leave-it contracts, design benefits that move patients to affiliated pharmacies, and then expand its own retail footprint as community pharmacies close, regulators should not treat that as a normal competitive market without looking closely.

That is exactly what Florida appears to be doing.

What should happen next

Florida should follow the evidence wherever it leads.

If the documents show fair, even-handed treatment, then the public should know that.

But if the documents show steering, reimbursement discrimination, audit asymmetry, restrictive contracting, or affiliate favoritism, then regulators should act.

That could mean:

• enforcement action;
• consent orders;
• restitution or penalties where appropriate;
• stronger state PBM enforcement;
• public reporting;
• coordination with other states;
• CMS action on reasonable-and-relevant Part D terms;
• stronger complaint channels for independent pharmacies;
• anti-retaliation protections with real consequences.

Independent pharmacies are not asking for special treatment. They are asking for a market where the company managing the benefit cannot quietly tilt the playing field toward its own stores.

Bottom line

Florida’s CVS/Caremark Civil Investigative Demand is significant because it turns a long-running independent pharmacy complaint into an evidence question.

For years, local pharmacies have warned that vertical PBM-pharmacy integration threatens their survival and patient access. Now Florida is asking for the documents and sworn testimony needed to test whether those warnings are supported by the facts.

That is the right question to ask.

Because if independent pharmacies are being underpaid, steered around, audited disproportionately, or trapped in unreasonable contracts while affiliated pharmacies receive better treatment, then the harm is not just to small businesses.

The harm is to patients, caregivers, seniors, rural communities, and every neighborhood that depends on a pharmacist who still answers the phone.

Sources

This article draws on:

• Florida Attorney General’s June 23, 2026 release announcing a Civil Investigative Demand to CVS Health Corporation and Caremark;
• Healthcare Dive coverage of CVS’s response and the broader state PBM-regulation context;
• NCPA coverage of the Florida investigation and independent pharmacy concerns;
• NCPA and Pharmacy Coalition advocacy around CMS reasonable-and-relevant Part D contract standards;
• NCPA summaries of 2026 Medicare Part D pharmacy reimbursement and PBM reform provisions.